MedTrace Logo

Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis

NCT07530367 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-08-03

No results posted yet for this study

Summary

Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Conditions

  • Palmoplantar Pustulosis (PPP)

Interventions

DRUG

Tofacitinib

11 mg tablet; administered orally once daily (QD)

DRUG

Imatinib

200 mg tablet; administered orally once daily (QD)

DRUG

tofacitinib Placebo

Matching placebo tablet; administered orally once daily (QD)

DRUG

Imatinib Placebo

Matching placebo tablet; administered orally once daily (QD)

Sponsors & Collaborators

  • Second Affiliated Hospital, Zhejiang University, School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-08-01
Completion
2030-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07530367 on ClinicalTrials.gov